Etanercept biosimilar - Mycenax Biotech/TSH Biopharm

Drug Profile

Etanercept biosimilar - Mycenax Biotech/TSH Biopharm

Alternative Names: E11; ENIA11; TNF-alphaR-Fc; TuNEX

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mycenax Biotech; TSH Biopharm
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Rheumatoid arthritis
  • Phase III Ankylosing spondylitis

Most Recent Events

  • 12 Jul 2017 Registered for Rheumatoid arthritis in Taiwan (SC)
  • 01 Jul 2017 Preregistration for Rheumatoid arthritis in Taiwan (SC) (Mycenax Biotech and TSH Biopharm pipeline, August 2017)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top